Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Evelo Biosciences, Inc. (EVLO)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Biotechnology
Address
620 Memorial Drive 2139
Cambridge, MA, US
Cambridge, MA, US
CEO
Craig R. Jalbert
Website
evelobio.com
IPO
2018-05-08
CIK 1694665 ISIN US2997342025
Description
Evelo Biosciences, Inc. is a biotechnology firm dedicated to identifying and advancing oral biologic therapies for various inflammatory conditions and oncological diseases. Its pipeline includes EDP1815, a whole-microbe compound designed to address inflammatory ailments, currently undergoing Phase 2 clinical trials for conditions such as psoriasis and atopic dermatitis, and also being evaluated for the hyperinflammatory reaction associated with COVID-19. Additional developments include EDP1867, an inactivated oral biologic in Phase 1b for inflammatory diseases; EDP2939, an investigational oral biologic based on extracellular vesicles targeting inflammatory diseases; and EDP1908, a drug candidate focused on cancer. Established in 2014, Evelo Biosciences, Inc. operates from its headquarters in Cambridge, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
506
Beta
1.32
Float Shares
18.90M
Free Float %
99.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | -80.00% | -80.00% | -75.00% | -100.00% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (8 ratings, all time)
Buy
Price Targets & DCF
Current price
0.00
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-53.28
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
3 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+43.1% ★ Q3'23: -1,156.5% (vs Q3'22)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q3'23: +447.2% (vs Q3'22)
-
Share dilution Biotechnology: -3.4%+64.8% Q3'23: -96.8% (vs Q3'22)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.48× Q3'23: -0.77× (vs Q3'22)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 EPS Ana. |
Dec 2027 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
—
|
—
est.
|
—
est.
|
—
est.
|
—
— – —
|
—
— – —
|
| EBITDA |
-106.35M
|
—
est.
|
—
est.
|
—
est.
|
—
— – —
|
—
— – —
|
| EBIT |
-108.93M
|
—
est.
|
—
est.
|
—
est.
|
—
— – —
|
—
— – —
|
| Net Income |
-114.53M
est: -117.10M (+2.2%)
|
-9.85M
est.
|
-11.20M
est.
|
-9.20M
est.
|
-6.10M
-6.10M – -6.10M
+33.6% YoY
|
-6.10M
-6.10M – -6.10M
+0.0% YoY
|
| SGA |
29.91M
|
—
est.
|
—
est.
|
—
est.
|
—
— – —
|
—
— – —
|
| EPS |
-26.28
est: -26.87 (+2.2%)
|
-2.26
est.
|
-2.57
est.
|
-2.11
est.
|
-1.40
-1.40 – -1.40
+33.6% YoY
|
-1.40
-1.40 – -1.40
+0.0% YoY
|
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
14
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 10 | 3.06M | 6.60% | — | 3.06M | — | 3.06M | IA | Delaware | 2021-02-16 | ↗ |
| 2 | CREDIT SUISSE AG/000000000 | 2.71M | 5.00% | — | 2.71M | — | 2.71M | BK, HC | — | 2021-02-12 | ↗ |
| 3 | Abigail P. Johnson | 2.45M | 14.75% | — | — | 2.45M | — | IN | United States of America | 2023-08-10 | ↗ |
| 4 | FMR LLC | 2.45M | 14.75% | 2.45M | — | 2.45M | — | HC | Delaware | 2023-08-10 | ↗ |
| 5 | Horizon Technology Finance Corporation | 2.16M | 11.50% | 2.16M | — | 2.16M | — | IV | Delaware | 2023-07-21 | ↗ |
| 6 | 1,763,505 | 1.76M | 5.50% | 1.76M | — | 1.76M | — | OO | Delaware | 2018-05-21 | ↗ |
| 7 | HVST-TOPE LLC | 1.45M | 8.80% | — | 1.45M | — | 1.45M | OO | Delaware | 2023-07-21 | ↗ |
| 8 | HarbourVest Partners L.P. | 1.45M | 8.80% | — | 1.45M | — | 1.45M | IA | Delaware | 2023-07-21 | ↗ |
| 9 | SMRS-TOPE LLC | 1.45M | 8.80% | 1.45M | — | 1.45M | — | OO | Delaware | 2023-07-21 | ↗ |
| 10 | GP LP | 379.5K | 8.30% | 379.5K | — | 379.5K | — | PN | United Kingdom | 2018-05-18 | ↗ |
| 11 | General Partner LLP | 379.5K | 8.30% | 379.5K | — | 379.5K | — | PN | United Kingdom | 2018-05-18 | ↗ |
| 12 | LLP | 379.5K | 8.30% | 379.5K | — | 379.5K | — | PN | United Kingdom | 2018-05-18 | ↗ |
| 13 | LP | 379.5K | 8.30% | 379.5K | — | 379.5K | — | PN | United Kingdom | 2018-05-18 | ↗ |
| 14 | DNCA FINANCE S.C.S | 920.00 | 3.63% | 920.00 | — | 920.00 | — | IV | — | 2022-08-23 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.50
Neutral
Ratio by volume
0.69
Neutral
Buys
7
Sells
14
Shares acquired
58.3K
Shares disposed
84.3K
Cash buys
—
Cash sales
7.00
Net activity
-25,956
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-11-08 | Thorell Marella | Officer | S-Sale | D | Common Stock | 1,811 | 0.33 | 597.63 | 22,259 | — | ↗ |
| 2023-11-08 | McHale Duncan | Officer | S-Sale | D | Common Stock | 3,103 | 0.33 | 1.0K | 16,984 | — | ↗ |
| 2023-11-08 | GILL SIMBA | Director / Officer | S-Sale | D | Common Stock | 172 | 0.33 | 56.76 | 17,758 | — | ↗ |
| 2023-11-08 | Bodmer Mark | Officer | S-Sale | D | Common Stock | 3,163 | 0.33 | 1.0K | 25,732 | — | ↗ |
| 2023-11-07 | Thorell Marella | Officer | M-Exempt | A | Common Stock | 6,500 | 0.00 | — | 24,070 | — | ↗ |
| 2023-11-07 | McHale Duncan | Officer | M-Exempt | A | Common Stock | 6,500 | 0.00 | — | 20,087 | — | ↗ |
| 2023-11-07 | GILL SIMBA | Director / Officer | M-Exempt | A | Common Stock | 1,172 | 0.00 | — | 17,930 | — | ↗ |
| 2023-11-07 | Bodmer Mark | Officer | M-Exempt | A | Common Stock | 6,625 | 0.00 | — | 28,895 | — | ↗ |
| 2023-11-02 | Thorell Marella | Officer | S-Sale | D | Common Stock | 3,999 | 0.33 | 1.3K | 17,570 | — | ↗ |
| 2023-11-02 | McHale Duncan | Officer | S-Sale | D | Common Stock | 6,854 | 0.33 | 2.3K | 13,587 | — | ↗ |
| 2023-11-02 | Bodmer Mark | Officer | S-Sale | D | Common Stock | 6,854 | 0.33 | 2.3K | 22,270 | — | ↗ |
| 2023-11-01 | Thorell Marella | Officer | M-Exempt | D | Restricted Stock Units | 12,500 | 0.00 | — | 25,000 | — | ↗ |
| 2023-11-01 | McHale Duncan | Officer | M-Exempt | D | Restricted Stock Units | 12,500 | 0.00 | — | 25,000 | — | ↗ |
| 2023-11-01 | Bodmer Mark | Officer | M-Exempt | D | Restricted Stock Units | 12,500 | 0.00 | — | 25,000 | — | ↗ |
| 2023-09-28 | GILL SIMBA | Director / Officer | S-Sale | D | Common Stock | 1,996 | 3.94 | 7.9K | 16,758 | — | ↗ |
| 2023-09-27 | GILL SIMBA | Director / Officer | A-Award | A | Restricted Stock Units | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2023-09-11 | Thorell Marella | Officer | A-Award | A | Restricted Stock Units | 37,500 | 0.00 | — | 37,500 | — | ↗ |
| 2023-09-11 | McHale Duncan | Officer | A-Award | A | Restricted Stock Units | 37,500 | 0.00 | — | 37,500 | — | ↗ |
| 2023-09-11 | Bodmer Mark | Officer | A-Award | A | Restricted Stock Units | 37,500 | 0.00 | — | 37,500 | — | ↗ |
| 2023-08-08 | Thorell Marella | Officer | S-Sale | D | Common Stock | 2,004 | 9.51 | 19.1K | 9,069 | — | ↗ |
| 2023-08-08 | McHale Duncan | Officer | S-Sale | D | Common Stock | 3,434 | 9.51 | 32.7K | 7,941 | — | ↗ |
| 2023-08-08 | GILL SIMBA | Director / Officer | S-Sale | D | Common Stock | 342 | 9.51 | 3.3K | 3,754 | — | ↗ |
| 2023-08-08 | Bodmer Mark | Officer | S-Sale | D | Common Stock | 3,128 | 9.51 | 29.7K | 16,624 | — | ↗ |
| 2023-08-07 | Thorell Marella | Officer | M-Exempt | D | Restricted Stock Units | 6,500 | 0.00 | — | 13,000 | — | ↗ |
| 2023-08-07 | McHale Duncan | Officer | M-Exempt | D | Restricted Stock Units | 6,500 | 0.00 | — | 13,000 | — | ↗ |
| 2023-08-07 | GILL SIMBA | Director / Officer | M-Exempt | A | Common Stock | 1,171 | 0.00 | — | 4,096 | — | ↗ |
| 2023-08-07 | Bodmer Mark | Officer | M-Exempt | D | Restricted Stock Units | 6,625 | 0.00 | — | 13,250 | — | ↗ |
| 2023-07-11 | Reynolds Alexander C | Director | A-Award | A | Stock Option (Right to Buy) | 2,000 | 3.38 | 6.8K | 2,000 | — | ↗ |
| 2023-07-11 | Moore Jeffrey R. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-07-11 | Horizon Technology Finance Corp | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 2,164,502 | — | ↗ |
| 2023-07-11 | Flagship Ventures Fund IV General Partner LLC | 10% Owner | P-Purchase | A | Common Stock | 1,082,251 | 2.31 | 2.50M | 1,461,795 | — | ↗ |
| 2023-06-08 | Williams Tonya | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.11 | 2.2K | 20,000 | — | ↗ |
| 2023-06-08 | Rosiello Robert L. | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.11 | 3.3K | 30,000 | — | ↗ |
| 2023-06-08 | McInnes Iain B. | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.11 | 2.2K | 20,000 | — | ↗ |
| 2023-06-08 | McHugh Julie | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.11 | 2.2K | 20,000 | — | ↗ |
| 2023-06-08 | MELAS KYRIAZI THEO | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.11 | 2.2K | 20,000 | — | ↗ |
| 2023-06-08 | Hohneker John | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.11 | 2.2K | 20,000 | — | ↗ |
| 2023-06-08 | Gutierrez-Ramos Jose-Carlos | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.11 | 2.2K | 20,000 | — | ↗ |
| 2023-06-08 | GILL SIMBA | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,000,000 | 0.97 | 970.0K | 1,000,000 | — | ↗ |
| 2023-06-08 | Andres Juan | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.11 | 2.2K | 20,000 | — | ↗ |
| 2023-05-23 | Bodmer Mark | Officer | S-Sale | D | Common Stock | 22,571 | 0.14 | 3.2K | 262,557 | — | ↗ |
| 2023-05-08 | Thorell Marella | Officer | S-Sale | D | Common Stock | 38,531 | 0.13 | 4.8K | 91,469 | — | ↗ |
| 2023-05-08 | McHale Duncan | Officer | S-Sale | D | Common Stock | 66,730 | 0.13 | 8.4K | 97,516 | — | ↗ |
| 2023-05-08 | GILL SIMBA | Director / Officer | S-Sale | D | Common Stock | 3,537 | 0.13 | 443.89 | 58,512 | — | ↗ |
| 2023-05-08 | Bodmer Mark | Officer | S-Sale | D | Common Stock | 68,014 | 0.13 | 8.5K | 285,128 | — | ↗ |
| 2023-05-07 | Thorell Marella | Officer | M-Exempt | D | Restricted Stock Units | 130,000 | 0.00 | — | 390,000 | — | ↗ |
| 2023-05-07 | McHale Duncan | Officer | M-Exempt | A | Common Stock | 130,000 | 0.00 | — | 164,246 | — | ↗ |
| 2023-05-07 | GILL SIMBA | Director / Officer | M-Exempt | A | Common Stock | 23,437 | 0.00 | — | 62,049 | — | ↗ |
| 2023-05-07 | Bodmer Mark | Officer | M-Exempt | A | Common Stock | 132,500 | 0.00 | — | 353,142 | — | ↗ |
| 2023-04-14 | Rosiello Robert L. | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 0.17 | 6.8K | 40,000 | — | ↗ |
| 2023-02-07 | Thorell Marella | Officer | A-Award | A | Restricted Stock Units | 520,000 | 0.00 | — | 520,000 | — | ↗ |
| 2023-02-07 | McHale Duncan | Officer | A-Award | A | Restricted Stock Units | 520,000 | 0.00 | — | 520,000 | — | ↗ |
| 2023-02-07 | GILL SIMBA | Director / Officer | A-Award | A | Restricted Stock Units | 375,000 | 0.00 | — | 375,000 | — | ↗ |
| 2023-02-07 | Bodmer Mark | Officer | A-Award | A | Restricted Stock Units | 530,000 | 0.00 | — | 530,000 | — | ↗ |
| 2023-01-31 | Plinio Mark D. | Officer | A-Award | A | Common Stock | 1,250 | 0.88 | 1.1K | 3,750 | — | ↗ |
| 2023-01-23 | CARRIERE STEPHEN J | Officer | S-Sale | D | Common Stock | 151 | 1.06 | 160.12 | 203 | — | ↗ |
| 2023-01-19 | CARRIERE STEPHEN J | Officer | M-Exempt | D | Restricted Stock Units | 354 | 0.00 | — | 1,063 | — | ↗ |
| 2022-09-01 | Thorell Marella | Officer | A-Award | A | Stock Option (Right to Buy) | 440,000 | 2.29 | 1.01M | 440,000 | — | ↗ |
| 2022-07-29 | Plinio Mark D. | Officer | A-Award | A | Common Stock | 1,250 | 1.79 | 2.2K | 2,500 | — | ↗ |
| 2022-07-19 | Zung Jonathan B. | Officer | A-Award | A | Stock Option (Right to Buy) | 115,000 | 0.00 | — | 115,000 | — | ↗ |
| 2022-07-19 | Char Daniel | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-07-13 | Thorell Marella | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-06-30 | Epstein David R | Director | M-Exempt | D | Restricted Stock Units | 2,874 | 0.00 | — | 0 | — | ↗ |
| 2022-06-10 | Epstein David R | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-10 | Darzi Lord Ara | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 2.02 | 60.6K | 30,000 | — | ↗ |
| 2022-06-09 | McInnes Iain B. | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-09 | McHugh Julie | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-09 | MELAS KYRIAZI THEO | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-09 | Hohneker John | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 2.60 | 52.0K | 20,000 | — | ↗ |
| 2022-06-09 | Darzi Lord Ara | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2022-06-09 | Andres Juan | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 2.60 | 52.0K | 20,000 | — | ↗ |
| 2022-05-31 | Epstein David R | Director | M-Exempt | D | Restricted Stock Units | 2,873 | 0.00 | — | 2,874 | — | ↗ |
| 2022-05-27 | McHale Duncan | Officer | P-Purchase | A | Common Stock | 34,246 | 1.46 | 50.0K | 34,246 | — | ↗ |
| 2022-05-27 | Flagship Ventures Fund IV General Partner LLC | 10% Owner | P-Purchase | A | Common Stock | 1,095,890 | 1.46 | 1.60M | 1,887,419 | — | ↗ |
| 2022-05-27 | Flagship Pioneering Fund VII General Partner LLC | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 13,698,630 | — | ↗ |
| 2022-05-27 | Epstein David R | Director | P-Purchase | A | Common Stock | 17,123 | 1.46 | 25.0K | 84,080 | — | ↗ |
| 2022-05-27 | Darzi Lord Ara | Director | P-Purchase | A | Common Stock | 342,465 | 1.46 | 500.0K | 342,465 | — | ↗ |
| 2022-05-27 | AFEYAN NOUBAR | Director | P-Purchase | A | Common Stock | 13,698,630 | 1.46 | 20.00M | 13,698,630 | — | ↗ |
| 2022-05-02 | Epstein David R | Director | M-Exempt | D | Restricted Stock Units | 2,873 | 0.00 | — | 5,747 | — | ↗ |
| 2022-04-01 | Williams Tonya | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-04-01 | Gutierrez-Ramos Jose-Carlos | Director | — | D | Common Stock | 0 | 0.00 | — | 10,000 | — | ↗ |
| 2022-03-31 | Epstein David R | Director | M-Exempt | A | Common Stock | 2,052 | 0.00 | — | 59,157 | — | ↗ |
| 2022-02-28 | Epstein David R | Director | M-Exempt | A | Common Stock | 2,873 | 0.00 | — | 57,105 | — | ↗ |
| 2022-01-31 | Plinio Mark D. | Officer | A-Award | A | Common Stock | 1,250 | 4.00 | 5.0K | 1,250 | — | ↗ |
| 2022-01-31 | Epstein David R | Director | M-Exempt | A | Common Stock | 2,873 | 0.00 | — | 52,179 | — | ↗ |
| 2022-01-19 | Zung Jonathan B. | Officer | A-Award | A | Stock Option (Right to Buy) | 115,000 | 5.05 | 580.8K | 115,000 | — | ↗ |
| 2022-01-19 | Scavo Luca | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 5.05 | 303.0K | 60,000 | — | ↗ |
| 2022-01-19 | Plinio Mark D. | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 5.05 | 303.0K | 60,000 | — | ↗ |
| 2022-01-19 | McHale Duncan | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 5.05 | 505.0K | 100,000 | — | ↗ |
| 2022-01-19 | GILL SIMBA | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 300,000 | 5.05 | 1.52M | 300,000 | — | ↗ |
| 2022-01-19 | Char Daniel | Officer | A-Award | A | Stock Option (Right to Buy) | 80,000 | 5.05 | 404.0K | 80,000 | — | ↗ |
| 2022-01-19 | CARRIERE STEPHEN J | Officer | A-Award | A | Restricted Stock Units | 1,417 | 0.00 | — | 1,417 | — | ↗ |
| 2022-01-19 | Bodmer Mark | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 5.05 | 631.3K | 125,000 | — | ↗ |
| 2021-12-31 | Epstein David R | Director | M-Exempt | A | Common Stock | 2,874 | 0.00 | — | 47,254 | — | ↗ |
| 2021-11-30 | Epstein David R | Director | M-Exempt | A | Common Stock | 2,053 | 0.00 | — | 39,455 | — | ↗ |
| 2021-11-01 | Epstein David R | Director | M-Exempt | A | Common Stock | 2,873 | 0.00 | — | 37,402 | — | ↗ |
| 2021-10-01 | Epstein David R | Director | M-Exempt | A | Common Stock | 2,053 | 0.00 | — | 29,603 | — | ↗ |
| 2021-09-29 | CARRIERE STEPHEN J | Officer | — | D | Stock Option (Right to Buy) | 75,000 | 11.22 | 841.5K | 0 | — | ↗ |
| 2021-09-03 | Epstein David R | Director | M-Exempt | D | Restricted Stock Units | 4,104 | 0.00 | — | 20,525 | — | ↗ |
| 2021-09-02 | McInnes Iain B. | Director | A-Award | A | Stock Option (Right to Buy) | 35,000 | 11.26 | 394.1K | 35,000 | — | ↗ |
| 2021-06-30 | Epstein David R | Director | A-Award | A | Restricted Stock Units | 34,480 | 0.00 | — | 34,480 | — | ↗ |
| 2021-06-14 | Plinio Mark D. | Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 16.34 | 4.09M | 250,000 | — | ↗ |
| 2021-06-09 | PERRY DAVID P | Director | A-Award | A | Stock Option (Right to Buy) | 1,810 | 14.19 | 25.7K | 1,810 | — | ↗ |
| 2021-06-09 | MELAS KYRIAZI THEO | Director | A-Award | A | Stock Option (Right to Buy) | 1,810 | 14.19 | 25.7K | 1,810 | — | ↗ |
| 2021-06-09 | Darzi Lord Ara | Director | A-Award | A | Stock Option (Right to Buy) | 1,810 | 14.19 | 25.7K | 1,810 | — | ↗ |
| 2021-06-09 | Andres Juan | Director | A-Award | A | Stock Option (Right to Buy) | 1,810 | 14.19 | 25.7K | 1,810 | — | ↗ |
| 2021-06-08 | PERRY DAVID P | Director | A-Award | A | Stock Option (Right to Buy) | 15,690 | 14.60 | 229.1K | 15,690 | — | ↗ |
| 2021-06-08 | MELAS KYRIAZI THEO | Director | A-Award | A | Stock Option (Right to Buy) | 15,690 | 14.60 | 229.1K | 15,690 | — | ↗ |
| 2021-06-08 | Darzi Lord Ara | Director | A-Award | A | Stock Option (Right to Buy) | 15,690 | 14.60 | 229.1K | 15,690 | — | ↗ |
| 2021-06-08 | Andres Juan | Director | A-Award | A | Stock Option (Right to Buy) | 15,690 | 14.60 | 229.1K | 15,690 | — | ↗ |
| 2021-06-01 | Scavo Luca | Officer | A-Award | A | Stock Option (Right to Buy) | 300,000 | 14.24 | 4.27M | 300,000 | — | ↗ |
| 2021-04-09 | McHugh Julie | Director | — | D | Stock Option (Right to Buy) | 11,768 | 3.95 | 46.5K | 0 | — | ↗ |
| 2021-02-02 | Flagship Ventures Fund IV General Partner LLC | 10% Owner | P-Purchase | A | Common Stock | 46,429 | 15.00 | 696.4K | 4,125,461 | — | ↗ |
| 2021-01-27 | Zung Jonathan B. | Officer | A-Award | A | Stock Option (Right to Buy) | 300,000 | 16.65 | 5.00M | 300,000 | — | ↗ |
| 2021-01-27 | McHale Duncan | Officer | A-Award | A | Stock Option (Right to Buy) | 96,500 | 16.65 | 1.61M | 96,500 | — | ↗ |
| 2021-01-27 | Liu Xiaoli Jacqueline | Officer | A-Award | A | Restricted Stock Units | 5,680 | 0.00 | — | 5,680 | — | ↗ |
| 2021-01-27 | Hohneker John | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-01-27 | GILL SIMBA | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 275,000 | 16.65 | 4.58M | 275,000 | — | ↗ |
| 2021-01-27 | Char Daniel | Officer | A-Award | A | Stock Option (Right to Buy) | 57,000 | 16.65 | 949.1K | 57,000 | — | ↗ |
| 2021-01-27 | Bodmer Mark | Officer | A-Award | A | Stock Option (Right to Buy) | 179,000 | 16.65 | 2.98M | 179,000 | — | ↗ |
| 2021-01-04 | Zung Jonathan B. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-11 | Epstein David R | Director | P-Purchase | A | Common Stock | 800 | 7.16 | 5.7K | 16,000 | — | ↗ |
| 2020-12-01 | Liu Xiaoli Jacqueline | Officer | S-Sale | D | Common Stock | 3,000 | 5.17 | 15.5K | 0 | — | ↗ |
| 2020-10-11 | Epstein David R | Director | A-Award | A | Stock Option (Right to Buy) | 59,395 | 5.66 | 336.2K | 59,395 | — | ↗ |
| 2020-08-31 | Epstein David R | Director | P-Purchase | A | Common Stock | 1,000 | 4.47 | 4.5K | 8,000 | — | ↗ |
| 2020-08-28 | Epstein David R | Director | P-Purchase | A | Common Stock | 3,248 | 4.40 | 14.3K | 4,248 | — | ↗ |
| 2020-07-10 | Liu Xiaoli Jacqueline | Officer | A-Award | A | Stock Option (Right to Buy) | 30,000 | 4.20 | 126.0K | 30,000 | — | ↗ |
| 2020-06-29 | Nutritional Health LTP Fund General Partner LLC | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,333,333 | — | ↗ |
| 2020-06-29 | Flagship Ventures Fund IV General Partner LLC | 10% Owner | P-Purchase | A | Common Stock | 333,333 | 3.75 | 1.25M | 782,244 | — | ↗ |
| 2020-06-17 | Simonian Nancy A | Director | A-Award | A | Stock Option (Right to Buy) | 15,690 | 3.59 | 56.3K | 15,690 | — | ↗ |
| 2020-06-17 | PERRY DAVID P | Director | A-Award | A | Stock Option (Right to Buy) | 15,690 | 3.59 | 56.3K | 15,690 | — | ↗ |
| 2020-06-17 | MELAS KYRIAZI THEO | Director | A-Award | A | Stock Option (Right to Buy) | 15,690 | 3.59 | 56.3K | 15,690 | — | ↗ |
| 2020-06-17 | Darzi Lord Ara | Director | A-Award | A | Stock Option (Right to Buy) | 15,690 | 3.59 | 56.3K | 15,690 | — | ↗ |
| 2020-06-17 | Andres Juan | Director | A-Award | A | Stock Option (Right to Buy) | 15,690 | 3.59 | 56.3K | 15,690 | — | ↗ |
| 2020-04-08 | Graham Neil | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 3.72 | 558.0K | 150,000 | — | ↗ |
| 2020-04-06 | Graham Neil | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-02-26 | Liu Xiaoli Jacqueline | Officer | — | D | Stock Option (Right to Buy) | 35,000 | 7.06 | 247.1K | 0 | — | ↗ |
| 2020-01-28 | Poole Jonathan | Officer | A-Award | A | Stock Option (Right to Buy) | 106,000 | 7.06 | 748.4K | 106,000 | — | ↗ |
| 2020-01-28 | McHale Duncan | Officer | A-Award | A | Stock Option (Right to Buy) | 117,000 | 7.06 | 826.0K | 117,000 | — | ↗ |
| 2020-01-28 | GILL SIMBA | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 7.06 | 1.77M | 250,000 | — | ↗ |
| 2020-01-28 | Char Daniel | Officer | A-Award | A | Stock Option (Right to Buy) | 35,000 | 7.06 | 247.1K | 35,000 | — | ↗ |
| 2020-01-28 | Bodmer Mark | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 7.06 | 706.0K | 100,000 | — | ↗ |
| 2019-12-04 | Andres Juan | Director | A-Award | A | Stock Option (Right to Buy) | 31,380 | 4.44 | 139.3K | 31,380 | — | ↗ |
| 2019-09-14 | Epstein David R | Director | A-Award | A | Stock Option (Right to Buy) | 75,000 | 7.93 | 594.8K | 75,000 | — | ↗ |
| 2019-06-12 | Simonian Nancy A | Director | A-Award | A | Stock Option (Right to Buy) | 15,690 | 7.07 | 110.9K | 15,690 | — | ↗ |
| 2019-06-12 | PERRY DAVID P | Director | A-Award | A | Stock Option (Right to Buy) | 15,690 | 7.07 | 110.9K | 15,690 | — | ↗ |
| 2019-06-12 | MELAS KYRIAZI THEO | Director | A-Award | A | Stock Option (Right to Buy) | 15,690 | 7.07 | 110.9K | 15,690 | — | ↗ |
| 2019-06-12 | Gutierrez-Ramos Jose-Carlos | Director | A-Award | A | Stock Option (Right to Buy) | 31,380 | 7.07 | 221.9K | 31,380 | — | ↗ |
| 2019-06-12 | Epstein David R | Director | A-Award | A | Stock Option (Right to Buy) | 15,690 | 7.07 | 110.9K | 15,690 | — | ↗ |
| 2019-06-12 | Darzi Lord Ara | Director | A-Award | A | Stock Option (Right to Buy) | 15,690 | 7.07 | 110.9K | 15,690 | — | ↗ |
| 2019-06-12 | AFEYAN NOUBAR | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 15,690 | 7.07 | 110.9K | 15,690 | — | ↗ |
| 2019-01-14 | Poole Jonathan | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 13.71 | 1.37M | 100,000 | — | ↗ |
| 2019-01-14 | GILL SIMBA | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 220,000 | 13.71 | 3.02M | 220,000 | — | ↗ |
| 2019-01-14 | Bodmer Mark | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 13.71 | 1.37M | 100,000 | — | ↗ |
| 2018-10-31 | Char Daniel | Officer | A-Award | A | Stock Option | 100,000 | 9.11 | 911.0K | 100,000 | — | ↗ |
| 2018-10-29 | Char Daniel | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-05-11 | Flagship Ventures Fund V General Partner LLC | 10% Owner | C-Conversion | D | Series A-1 Preferred Stock | 10,102,055 | 0.00 | — | 0 | — | ↗ |
| 2018-05-11 | Flagship Ventures Fund IV General Partner LLC | 10% Owner | C-Conversion | D | Series A-1 Preferred Stock | 10,102,055 | 0.00 | — | 0 | — | ↗ |
| 2018-05-11 | Alexandria Venture Investments, LLC | 10% Owner | C-Conversion | D | Series B preferred stock | 1,388,889 | 0.00 | — | 0 | — | ↗ |
| 2018-05-08 | Simonian Nancy A | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-05-08 | Poole Jonathan | Officer | — | D | Stock Option | 235,351 | 10.48 | 2.47M | 0 | — | ↗ |
| 2018-05-08 | PERRY DAVID P | Director | — | D | Stock Option | 35,750 | 0.54 | 19.3K | 0 | — | ↗ |
| 2018-05-08 | McHale Duncan | Officer | — | D | Stock Option | 82,740 | 3.96 | 327.7K | 0 | — | ↗ |
| 2018-05-08 | MELAS KYRIAZI THEO | Director | — | D | Stock Option | 56,386 | 2.49 | 140.4K | 0 | — | ↗ |
| 2018-05-08 | GILL SIMBA | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 38,612 | — | ↗ |
| 2018-05-08 | Flagship Ventures Fund V General Partner LLC | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 3,330,009 | — | ↗ |
| 2018-05-08 | Flagship Ventures Fund IV General Partner LLC | 10% Owner | — | I | Series A Preferred Stock | 3,073,533 | 0.00 | — | 0 | — | ↗ |
| 2018-05-08 | Epstein David R | Director | — | D | Stock Option | 98,063 | 2.49 | 244.2K | 0 | — | ↗ |
| 2018-05-08 | Darzi Lord Ara | Director | — | D | Stock Option | 63,741 | 10.48 | 668.0K | 0 | — | ↗ |
| 2018-05-08 | Bodmer Mark | Officer | — | D | Common Stock | 0 | 0.00 | — | 220,642 | — | ↗ |
| 2018-05-08 | Alexandria Venture Investments, LLC | 10% Owner | — | D | Series C preferred stock | 151,801 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
18.98M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2022 | Balkrishan (Simba) Gill, Ph.D. Chief Executive Officer | 585.0K | — | — | 1.14M | — | 385.00 | 1.72M | 66.00% | ↗ |
| 2 | 2022 | Jonathan Zung, Ph.D. Former Chief Development Officer | 432.0K | — | — | 627.3K | — | 48.2K | 1.11M | 56.64% | ↗ |
| 3 | 2022 | Marella Thorell Chief Financial Officer | 132.5K | 100.0K | — | 763.6K | — | 33.1K | 1.03M | 74.20% | ↗ |
| 4 | 2021 | Jonathan Zung, Ph.D. Former Chief Development Officer | 415.0K | 110.0K | 166.5K | 3.68M | 141.1K | 47.2K | 4.56M | 84.36% | ↗ |
| 5 | 2021 | Jonathan Zung, Ph.D. Chief Development Officer | 415.0K | 110.0K | 166.5K | 3.68M | 141.1K | 47.2K | 4.56M | 84.36% | ↗ |
| 6 | 2021 | Balkrishan (Simba) Gill, Ph.D. Chief Executive Officer | 575.0K | — | — | 3.37M | 268.8K | 509.00 | 4.22M | 79.98% | ↗ |
| 7 | 2021 | Luca Scavo Chief Financial Officer | 415.0K | 50.0K | 64.7K | 3.18M | 82.3K | 98.5K | 3.89M | 83.42% | ↗ |
| 8 | 2020 | Balkrishan (Simba) Gill, Ph.D. Chief Executive Officer | 560.0K | — | — | 1.21M | 400.4K | — | 2.17M | 55.71% | ↗ |
| 9 | 2020 | Duncan McHale, M.B.B.S., Ph.D. Chief Medical Officer | 409.0K | — | — | 565.4K | 228.3K | 24.7K | 1.23M | 46.07% | ↗ |
| 10 | 2020 | Mark Bodmer, Ph.D. Chief Scientific Officer | 440.0K | — | — | 483.3K | 228.8K | — | 1.15M | 41.95% | ↗ |
| 11 | 2019 | Balkrishan (Simba) Gill, Ph.D. Chief Executive Officer | 540.0K | — | — | 2.05M | 216.0K | — | 2.80M | 73.02% | ↗ |
| 12 | 2019 | Mark Bodmer, Ph.D. Chief Scientific Officer | 420.0K | — | — | 930.0K | 134.4K | 3.1K | 1.49M | 62.52% | ↗ |
| 13 | 2019 | Jonathan Poole Former Chief Financial Officer | 385.0K | — | — | 930.0K | 123.2K | 6.0K | 1.44M | 64.40% | ↗ |
| 14 | 2018 | Balkrishan (Simba) Gill, Ph.D. Chief Executive Officer | 491.8K | — | — | 3.68M | 300.0K | — | 4.47M | 82.28% | ↗ |
| 15 | 2018 | Jonathan Poole Former Chief Financial Officer | 276.9K | — | — | 2.49M | 252.8K | 2.5K | 3.02M | 82.36% | ↗ |
| 16 | 2018 | Jonathan Poole Chief Financial Officer and Treasurer | 276.9K | — | — | 2.49M | 252.8K | 2.5K | 3.02M | 82.36% | ↗ |
| 17 | 2018 | Duncan McHale, M.B.B.S., Ph.D. Chief Medical Officer | 371.2K | — | — | 1.74M | 161.3K | 20.1K | 2.29M | 75.87% | ↗ |
| 18 | 2017 | Balkrishan (Simba) Gill, Ph.D. Chief Executive Officer | 437.5K | — | — | 1.18M | 218.7K | — | 1.83M | 64.18% | ↗ |
| 19 | 2017 | Duncan McHale, M.B.B.S., Ph.D. Chief Medical Officer | 12.7K | — | — | 831.6K | — | 690.00 | 844.9K | 98.42% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Duncan McHale MBBS | Chief Medical Officer | 662.0K | — |
| Andrea Itano | Head of Research | — | — |
| Chun Zhang | Chief Technical Operations & Quality Officer | — | — |
| Craig R. Jalbert CIRA | President, Secretary, Principal Executive, Financial and Accounting Officer & Director | — | male |
| Douglas Maslin | Senior Director & Immunology Clinical Lead | — | male |
| Leslie Wardwell-Scott | Vice President and Head of Corporate Development & Strategic Integration | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EVLO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
